Novartis India to sell rifampicin drug business to Sandoz

Font Size

Print

Feedback

Email

Discuss

Related Articles

Sun Pharma’s net dips 11% on US salesEU anti-trust raid on Ranbaxy France unit

Mumbai, Jan 28: Novartis India, on Friday, said that it has decided to sell its rifampicin bulk drug business and Mahad facility to Sandoz Pvt Ltd for a consideration of Rs 30.77 crore.

The company in a statement, issued here, said the rifampicin business has been facing severe operational challenges for some time mainly due to surplus capacities, cheaper imports and falling domestic prices. “This has been a cause of concern for the company and after closely monitoring developments in the anti-TB market, the board decided to propose to the shareholders the sale of the company’s rifampicin bulk drug business together with its Mahad facility to Sandoz Pvt Ltd for a consideration of Rs 30.70 crore,” the statement said. This consideration will be suitably adjusted to represent any change in net asset value on the date of transaction.

The sale will be effective April 1, 2005 or any date thereafter. The company will seek shareholder’s approval of this proposal by postal ballot and necessary regulatory approval, the release added.